1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
638CB82581FB8E54F0025867A00409320
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-gathering-distributing-insights-within-medical-affairs-tools-activities-training-techniques?OpenDocument
18
19OpenDocument
2018.97.14.90
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Communication

Gathering and Distributing Insights within Medical Affairs: Insight Gathering Tools, Activities, and Training Techniques

ID: 5667


Features:

11 Info Graphics

49 Data Graphics

1500 Metrics

2 Narratives


Pages/Slides: 68


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Gathering and Distributing Insights within Medical Affairs: Insight Gathering Tools, Activities, and Training Techniques”

STUDY OVERVIEW

As important as it is, many organizations lack a clear approach for gathering Medical Insights that can help inform overall Medical Affairs strategies and plans. Indeed, the realm of Medical Insights and Intelligence - driven by dedicated resources, speed and new skills - is an area ripe for improvement for Medical Affairs groups across the biopharma industry.

Best Practices, LLC undertook this benchmarking research to identify the best practices for gathering insights within the Medical Affairs organization. The study provides benchmarks around coordination, activities, training techniques and tools required for effectively gathering insights.

Benchmark data in the study is broken down into three different segments to provide deeper insights. Classifications reflect their approach and standing on Medical insight generation: Insight Leaders (17 respondents), Insight Majority (56 respondents), and Insight Laggards (11 respondents).

KEY TOPICS

  • Insights Gathering Activities
  • Coordination for Insights Gathering
  • Training Techniques and Tools for Insights Gathering

KEY METRICS
  • For your current operating model, please rate the effectiveness of the listed tactics and tools that your Medical Affairs group uses to coordinate work, data, and analyses
  • Are different insights gathering tools/systems used at the same company depending on the (customer facing) Medical Affairs function?
  • What percentage of your intelligence gathering work involves primary (field) research and secondary research?
  • Please rate the effectiveness and importance of the listed sources for collecting intelligence data within Medical Affairs
  • Please rate the frequency of the listed primary and secondary sources for collecting intelligence data within Medical Affairs
  • Please rate the effectiveness of the listed internal sources that support intelligence data collection
  • Which functions and groups are used within your Medical Affairs organization to narrow the focus of the issue and discover information gaps?
  • Are there any limitations as to who can receive Medical insights internally?
  • How effective are the listed training techniques for insights data collection?

SAMPLE KEY FINDINGS
  • Insight Gathering Process and Its Effectiveness: Few conduct the Insight Process through a stand-alone group. Instead, they use various subfunctions to coordinate a slate of activities to ensure data is gathered and input into a system. They may choose to coordinate work across other inter-functional groups, often with limited success.

METHODOLOGY

Best Practices, LLC engaged 84 executives from 57 leading life sciences companies in this research. The study insights are mostly from directors and higher management executives, representing nearly 80% of the benchmark participants.

Industries Profiled:
Pharmaceutical; Biotech; Biopharmaceutical; Communications; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Clinical Research; Laboratories; Science


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Agios Pharmaceuticals; Alcon Laboratories; ALK Abelló; Alkermes; Amgen Inc.; Amicus Therapeutics; Apellis Pharmaceuticals; ApotheCom; AstraZeneca; B. Braun Medical Inc.; Bayer; Becton Dickinson; Biohaven Pharmaceuticals; bioMerieux; Boehringer Ingelheim; Clovis Oncology; CSL Behring; Daiichi Sankyo; Eisai; Eli Lilly and Company; EMD Serono; Fidia Pharma USA Inc.; Genentech; Getinge; GlaxoSmithKline; Ipsen; Janssen Pharmaceuticals Inc.; LEO; Lundbeck; Lupin Limited; Mallinckrodt Pharmaceuticals; Merck ; Merck KGaA; Merz Pharmaceuticals; Mesoblast; Novartis; Novo Nordisk; Nutricia; Orchard Therapeutics; Pfizer; Roche; SAGE Therapeutics; Sandoz Inc.; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Santen; Servier; Sunovion; Takeda; TerumoBCT; Teva Pharmaceuticals; Thermo Fisher Scientific; Vertex Pharmaceuticals; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.